-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $25

Benzinga·02/25/2026 15:53:57
Listen to the news
Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $48 to $25.